Celegence转发了
AI in regulatory affairs—an area where Celegence excels. At Celegence, our Tech-Enabled Services approach, powered by CAPTIS? AI, goes beyond automation, driving efficiency and optimizing business processes for medical device and pharmaceutical companies. This unique blend of technology and expertise sets us apart from other vendors, offering a seamless path to streamlined regulatory submissions. Unlike traditional Regulatory Affairs services, our focus on AI-driven optimization—such as automating CMC Module 3 for 50%+ efficiency gains—empowers companies to stay ahead in a competitive landscape. Join the leaders revolutionizing compliance and R&D with Celegence. #Tech-Enabled Services
Novo Nordisk A/S, the maker of Ozempic, has reduced clinical study report drafting time from 15 weeks to under 10 minutes using #AI. This demonstrates that AI is now advanced enough to create highly complex and sensitive #regulatory documents with precision. At Celegence, we see this impact firsthand. CAPTIS? AI is revolutionizing medical and technical writing, delivering: ??30% faster Clinical Evaluation Report (CER) creation ??60% reduction in systematic literature review time ??AI-driven precision and compliance for regulatory teams Beyond regulatory submissions, we’ve partnered with top-5 pharma clients to develop R&D-specific AI solutions. By integrating Retrieval-Augmented Generation (RAG) and automating #CMC Module 3, we’re targeting 50%+ efficiency gains in pharmaceutical submissions. ? Join leading #medicaldevice and #pharmaceutical companies adopting AI for regulatory writing and healthcare development: the future of compliance is AI-powered. ? ?? Book a demo of CAPTIS? AI: https://lnkd.in/e__vshzE ?? Source: https://lnkd.in/eqRpZ4Kc ? #AIinRegulatoryAffairs #MedicalWriting #RegulatoryCompliance #CAPTISAI #PharmaTech #ClinicalEvaluationReports #MedicalDevices